[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331763-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331763-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mir-181a-regulatory-roles-cancer-associated-signaling-pathway-disruptions-and-therapeutic-potential","miR-181a - regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential","","microRNA-181a (miR-181a) functions as a key post-transcriptional regulator of many mRNA transcripts and noncoding RNAs, shaping proliferation, cancer stemness, apoptosis, and immune responses. Abnormal miR-181a expression is documented across multiple cancers, supporting its value as a genomic vulnerability and biomarker. The article reviews links between miR-181a and poor patient outcomes, details mechanisms of miR-181a activity and processing, and maps its roles across regulatory cancer signaling pathways, cellular processes, and the tumor microenvironment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mir-181a-regulatory-roles-cancer-associated-signaling-pathway-disruptions-and-therapeutic-potential/331763/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mir-181a-regulatory-roles-cancer-associated-signaling-pathway-disruptions-and-therapeutic-potential/331763.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological functions does miR-181a regulate in cancer?","Question",{"text":63,"@type":64},"miR-181a regulates post-transcriptional control of transcripts involved in cell proliferation, cancer stemness, apoptosis, and immune responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is miR-181a processed and matured according to the article?",{"text":68,"@type":64},"Pri-miRNA is generated in the nucleus and processed by DROSHA/DGCR8 into pre-miRNA, which is exported to the cytoplasm; DICER and TRBP then produce the mature miRNA duplex.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is miR-181a considered a clinically relevant target for therapy?",{"text":72,"@type":64},"It is described as a pan-cancer biomarker with therapeutic potential because it controls tumorigenic signaling pathways and immune responses, though success depends on developing specific therapeutics platforms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331763,1790696838,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Expert Opin Ther Targets. Author manuscript; available in PMC 2025 May 06. |\n| --- | --- |\n\nPublished in final edited form as:  \nExpert Opin Ther Targets. 2024 December ; 28(12): 1061–1091. doi:10.1080/14728222.2024.2433687 .  \nmiR-181a: regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential  \nGrace McIntyrea,b, Zoe Jacksonc, Jose Colinaa,b, Sreeja Sekhara,b, Analisa DiFeoa,ba Department of Pathology, Rackham Graduate School, University of Michigan, Ann Arbor, MI, USA  \nbRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA  \nc Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA  \nAbstract  \nIntroduction: microRNA-181a ( miR-181a) is a crucial post-transcriptional regulator of many mRNA transcripts and noncoding-RNAs, influencing cell proliferation, cancer cell stemness, apoptosis, and immune responses. Its abnormal expression is well-characterized in numerous cancers, establishing it as a significant genomic vulnerability and biomarker in cancer research.  \nAreas covered: Here, we summarize miR-181a’s correlation with poor patient outcomes across numerous cancers and the mechanisms governing miR-181a’s activity and processing.  \nWe comprehensively describe miR-181a’s involvement in multiple regulatory cancer signaling pathways, cellular processes, and the tumor microenvironment. We also discuss current therapeutic approaches to targeting miR-181a, highlighting their limitations and future potential.  \nExpert opinion: miR-181ais a clinically relevant pan-cancer biomarker with potential as a therapeutic target. Its regulatory control of tumorigenic signaling pathways and immune responses positions it as a promising candidate for personalized treatments. The success of miR-181a as a target relies on the development of specific therapeutics platforms. Future research on miR-181a’s role in the tumor microenvironment and the RNA binding proteins that regulate its stability will help uncover new techniques to targeting miR-181a. Further research into miR-181a serum levels in patients undergoing therapy will help to better stratify patients and enhance therapeutic success.  \nKeywords  \nBiomarker; cancer; miR-181a ; microRNA ; microRNA therapeutics; microRNA processing;  \nmicroRNA regulation; signaling pathways  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.  \nCONTACT Analisa DiFeo adifeo@umich.edu Department of Pathology, Rackham Graduate School, University of Michigan, 1150 W Medical Center Dr. Ste 752, Ann Arbor, MI 48109, USA.  \nDeclaration of interest  \nThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nMcIntyre et al. Page 2  \n1. Introduction  \nCancer arises when normal cellular processes become disrupted. Tumor suppressive redundancies, feedback loops, extrinsic immune surveillance, programmed cell death, and other mechanisms exist to guard against transformation. When these mechanisms fail, neoplasia and carcinogenesis result as competitive advantages that overcome these defenses, permitting cell survival, proliferation, and metastasis. Countless happenstances can result in tr","cbCaihSakxqT6M5Y","https://ap.wps.com/l/cbCaihSakxqT6M5Y","pdf",2390342,64,"English","# Abstract\n# Introduction\n## microRNA-181a as a regulatory microRNA\n## miRNA biogenesis and processing overview\n# Areas covered\n## Patient outcome correlations\n## Mechanisms of miR-181a activity and processing\n## Regulatory cancer signaling pathways\n## Tumor microenvironment involvement\n# Expert opinion\n## Therapeutic targeting and biomarker relevance\n## Future research directions","[{\"question\":\"What biological functions does miR-181a regulate in cancer?\",\"answer\":\"miR-181a regulates post-transcriptional control of transcripts involved in cell proliferation, cancer stemness, apoptosis, and immune responses.\"},{\"question\":\"How is miR-181a processed and matured according to the article?\",\"answer\":\"Pri-miRNA is generated in the nucleus and processed by DROSHA/DGCR8 into pre-miRNA, which is exported to the cytoplasm; DICER and TRBP then produce the mature miRNA duplex.\"},{\"question\":\"Why is miR-181a considered a clinically relevant target for therapy?\",\"answer\":\"It is described as a pan-cancer biomarker with therapeutic potential because it controls tumorigenic signaling pathways and immune responses, though success depends on developing specific therapeutics platforms.\"}]","miR-181a - regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential | PDF",1789995009,161]